Juying Wei

1PUBLICATIONS
2CO-AUTHORS
Predictive and prognostic markers
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (1)

|Mar 18, 2026
Phase 2 multicenter maintenance study of golidocitinib, A JAK1 selective inhibitor, in patients with peripheral T cell lymphomas after first-line systemic therapy (JACKPOT26).

Juying Wei, Qingqing Cai, Liling Zhang

Pageof 1

Frequent Collaborators

1 joint publications

Qingqing Cai

1 joint publications

Jie Jin